WO2007017264A3 - Pyrrolopyridinederivatives as modulators of the cannabinoid receptor for the treatment of immune and inflammatory disorders - Google Patents
Pyrrolopyridinederivatives as modulators of the cannabinoid receptor for the treatment of immune and inflammatory disorders Download PDFInfo
- Publication number
- WO2007017264A3 WO2007017264A3 PCT/EP2006/007875 EP2006007875W WO2007017264A3 WO 2007017264 A3 WO2007017264 A3 WO 2007017264A3 EP 2006007875 W EP2006007875 W EP 2006007875W WO 2007017264 A3 WO2007017264 A3 WO 2007017264A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- group
- hydrogen
- substituted
- cycloalkyl
- Prior art date
Links
- 102000018208 Cannabinoid Receptor Human genes 0.000 title abstract 2
- 108050007331 Cannabinoid receptor Proteins 0.000 title abstract 2
- 208000026278 immune system disease Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000005255 pyrrolopyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to novel pyrrolopyridine derivatives of formula (I), pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease-in activity of the cannabinoid receptor, wherein: X1 is NH and X2 and X3 together form a -CR13=CR11-group or X3 is NR12 and X2 and X1 together form a -CR13=CR11- group; X4 is O, SO2, S, or a bond, or X4 is -NHCO or -NHCH2 such that R6X4 is R6CONH or R6CH2NH; R1 is selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl and halosubstituted C1-6 alkyl; R2 is hydrogen or (CH2)mR3 where m is 0 or 1; or R1 and R2 together with N to which they are attached form an optionally substituted 4- to 8- membered non-aromatic heterocyclyl ring; R3 is a 4- to8- membered non-aromatic heterocyclyl group, a C3-8 cycloalkyl group, a straight or branched C1-10 alkyl, a C2-10 alkenyl, a C3-8 cycloalkenyl, a C2-10 alkynyl, a C3-8 cycloalkynyl or phenyl group, any of which can be unsubstituted or substituted, or R5; wherein p is 0, 1 or 2, and X is CH2. O, S, or SO2; R6 is phenyl, C3-6 cycloalkyl, a straight or branched C1-6 alkyl group, -CH2-C3-6 cycloalkyl, -CH2-phenyl, 4- to 8- membered non-aromatic heterocyclyl group, or a bicyclic group any of which can be unsubstituted or substituted, however when X4 is a bond R6 is substituted phenyl; R7 is OH, C1-6 alkoxy, NR8aR8b, NHCOR9, NHSO2R9 or SOqR9; R8a is H or C1-6 alkyl; R8b is Hor C1-6 alkyl; R9 is C1-6 alkyl; R10 is hydrogen, substituted or unsubstituted (C1-6)alkyl or chloro; R11 is hydrogen or C1-6 alkyl; R12 is hydrogen or C1-6 alkyl; R13 is hydrogen or C1-6 alkyl; q is 0, 1 or 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0516379.5A GB0516379D0 (en) | 2005-08-09 | 2005-08-09 | Compounds |
| GB0516379.5 | 2005-08-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007017264A2 WO2007017264A2 (en) | 2007-02-15 |
| WO2007017264A3 true WO2007017264A3 (en) | 2007-04-12 |
Family
ID=34984350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2006/007875 WO2007017264A2 (en) | 2005-08-09 | 2006-08-07 | Pyrrolopyridinederivatives as modulators of the cannabinoid receptor for the treatment of immune and inflammatory disorders |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB0516379D0 (en) |
| WO (1) | WO2007017264A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101257550B1 (en) | 2007-09-10 | 2013-04-24 | 칼시메디카, 인크 | Compounds that regulate intracellular calcium |
| SI2215071T1 (en) | 2007-11-30 | 2015-12-31 | Zynerba Pharmaceuticals, Inc. | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same |
| WO2009076454A2 (en) * | 2007-12-12 | 2009-06-18 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| BRPI0917719A2 (en) | 2008-08-27 | 2019-11-19 | Calcimedica Inc | intracellular calcium modulating compounds |
| US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| EP2415765A4 (en) | 2009-03-30 | 2012-08-15 | Astellas Pharma Inc | Pyrimidine compound |
| US8618307B2 (en) | 2009-09-16 | 2013-12-31 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AU2011283563C1 (en) | 2010-07-29 | 2015-01-22 | Astellas Pharma Inc. | Condensed ring pyridine compound |
| AU2013353004A1 (en) * | 2012-11-30 | 2015-07-09 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound |
| CN110627846B (en) * | 2019-10-30 | 2022-11-29 | 河南师范大学 | Galactoside-tetraphenylethylene compound and its preparation method and its application as a drug carrier |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058869A2 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| US20020022624A1 (en) * | 2000-07-13 | 2002-02-21 | Kevin Dinnell | Azaindole derivatives and their use as therapeutic agents |
| WO2005066126A1 (en) * | 2003-12-23 | 2005-07-21 | Eli Lilly And Company | Cb1 modulator compounds |
| WO2005121140A1 (en) * | 2004-06-09 | 2005-12-22 | Glaxo Group Limited | Pyrrolopyridine derivatives |
-
2005
- 2005-08-09 GB GBGB0516379.5A patent/GB0516379D0/en not_active Ceased
-
2006
- 2006-08-07 WO PCT/EP2006/007875 patent/WO2007017264A2/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058869A2 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| US20020022624A1 (en) * | 2000-07-13 | 2002-02-21 | Kevin Dinnell | Azaindole derivatives and their use as therapeutic agents |
| WO2005066126A1 (en) * | 2003-12-23 | 2005-07-21 | Eli Lilly And Company | Cb1 modulator compounds |
| WO2005121140A1 (en) * | 2004-06-09 | 2005-12-22 | Glaxo Group Limited | Pyrrolopyridine derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007017264A2 (en) | 2007-02-15 |
| GB0516379D0 (en) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007017264A3 (en) | Pyrrolopyridinederivatives as modulators of the cannabinoid receptor for the treatment of immune and inflammatory disorders | |
| MA32175B1 (en) | Oxadiazoanthracenes for the treatment of diabetes | |
| NO20070347L (en) | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic applications | |
| WO2007006926A3 (en) | Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors | |
| MY149070A (en) | 1h-quinazoline-2,4-diones | |
| MX2009009447A (en) | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof. | |
| MX2010010131A (en) | Herbicidal coumpounds. | |
| NO20090760L (en) | Novel tricyclic spiropiperidine compounds, their syntheses and their applications as modulators of chemokine receptor activity | |
| IL189298A0 (en) | 3.5-disubstituted phenyl-piperidines as modulators of dopamine meurotransmission | |
| NO20073019L (en) | Pyrasolone compounds as metabotropic glutamate receptor antagonists for the treatment of neurotic and psychiatric disorders | |
| NO20071642L (en) | N-Benzenesulfonyl-substituted anilino-pyrimidine analogs | |
| EA201391158A1 (en) | DIAMINIC PHENOTIAZINE SALTS AND THEIR APPLICATION | |
| CY1107956T1 (en) | USE OF 2-AMINOTETRALINE SUBSTITUTES FOR PREVENTIVE TREATMENT OF PARKINS DISEASE | |
| WO2008099072A3 (en) | New 2, 4-dianilinopyrimidines, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors | |
| ATE484502T1 (en) | NEW CONNECTIONS | |
| AR050158A1 (en) | COMPOUND DERIVED FROM PIRROLOPIRIDINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO MANUFACTURE SUCH COMPOSITION | |
| TW200621760A (en) | 2-morpholino-4-pyrimidone compound | |
| MX2009012471A (en) | 4' substituted compounds having 5-ht6 receptor affinity. | |
| EA201001586A1 (en) | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | |
| WO2008077810A3 (en) | Spiro-piperidine derivatives | |
| IN2012DN03343A (en) | ||
| MA33103B1 (en) | Derivatives 6 - (substitute 6 - triazolopridzine - sulfanil 5) (A-fluoro-benzotiazole and 5-fluoro-benzimidazole: preparation and use as drugs and as inhibitors) | |
| WO2009034432A3 (en) | Novel compounds active as muscarinic receptor antagonists | |
| AR070077A1 (en) | N-FENIL COMPOUNDS - IMIDAZO (1,2-A) PIRIDIN -2- CARBOXAMIDS, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | |
| DE602007005387D1 (en) | PTORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008109648 Country of ref document: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06776703 Country of ref document: EP Kind code of ref document: A2 |